PITPNM3 and neoplasm: Blocking CCL18–PITPNM3 signaling could not only impede tumor cell metastasis, reverse immunosuppression, suppress angiogenesis and inhibit tumor progression but also block the evolution of tumor-promoting CAFs in the early stage of tumor progression.